Search Results

Viewing Page 4 of 20 | Showing results 31 - 40 of 194

A Phase 1 study of the highly-selective RET Inhibitor, BLU-667, in patients with thyroid cancer, non-small cell lung cancer (NSCLC) and other advanced solid tumors

UCI Health is conducting a Phase 1 clinical trial of the highly-selective RET Inhibitor, BLU-667, in patients with thyroid cancer, non-small cell...
Viola W. Zhu, MD
Viola W. Zhu, MD
Open